Filing Flows › Health Care › Harvard Apparatus Regenerative Technology (HRGN)
Harvard Apparatus Regenerative Technology (HRGN) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Harvard Apparatus Regenerative Technology (HRGN) Q2 2026 earnings results →
Q2 2026 Revenue up 31% year over year to $414K · 409¢ of every $1 of revenue lost · operating margin -408.7%
Harvard Apparatus Regenerative Technology made $414K in Q2 2026 (+31% Y/Y). Operating margin -408.7%, net loss $1.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $414K in Q2 2026, up 31% year over year and up 83% from the previous quarter.
Operating costs exceeded revenue by $1.7M, an operating margin of -408.7%. Total costs fell 2% while revenue rose 31%. The fastest-growing cost line was Research & development (+36%). The quarter ended with a net loss of $1.7M, wider than the previous quarter's $1.6M loss.
Operating cash flow was −$569K. Non-cash charges added back $1K of depreciation and $223K of share-based compensation. Working capital and other items added $902K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $414K | +31% | -408.7% | −$1.7M | −$569K |
| Q1 2026 | 10-Q | May 13, 2026 | $226K | +402% | -710.6% | −$1.6M | −$937K |
| Q4 2025 | 10-K | Mar 19, 2026 | $219K | -15% | -775.3% | −$1.7M | −$664K |
| Q3 2025 | 10-Q | Nov 7, 2025 | $123K | +108% | n/m | −$1.7M | −$1.5M |
| Q2 2025 | 10-Q | Aug 11, 2025 | $317K | +466% | -578.2% | −$1.8M | −$941K |
| Q1 2025 | 10-Q | May 14, 2025 | $45K | -21% | n/m | −$1.7M | −$758K |
| Q4 2024 | 10-K | Mar 31, 2025 | $258K | +310% | -529.1% | −$1.3M | −$1.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Harvard Apparatus Regenerative Technology
We are a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastro-intestinal system and other organs that result from cancer, trauma or birth defects. Our technology is based on our proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. We believe that our technology represents a next generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrificing of another of the patient’s own organs or permanent artificial implants.
In its own words, from its 10-K, filed Mar 19, 2026.
Harvard Apparatus Regenerative Technology against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +31% against the peers' median +5%. Operating margin: -408.7% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| HRGN Harvard Apparatus Regenerative Technology | Q2 2026 | $414K | +31% | -408.7% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Harvard Apparatus Regenerative Technology 10-Q on SEC EDGAR · CIK 1563665 · Surgical & Medical Instruments & Apparatus
More on HRGN
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results
Compare HRGN with
- Harvard Apparatus Regenerative Technology vs Family Office of America (HRGN vs FOFA)
- Harvard Apparatus Regenerative Technology vs Vycor Medical (HRGN vs VYCO)
- Harvard Apparatus Regenerative Technology vs Cerenome (HRGN vs CNSY)
- Harvard Apparatus Regenerative Technology vs Pulse Biosciences (HRGN vs PLSE)